Article Versions Notes

Kan T-C, Lin M-H, Cheng C-C, Lu J-W, Sheu M-T, Ho Y-S, Rahayu S, Chang J. Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers. Pharmaceutics. 2022; 14(4):839. https://doi.org/10.3390/pharmaceutics14040839

Kan, Tzu-Chun, Mei-Hsiang Lin, Chun-Chia Cheng, Jeng-Wei Lu, Ming-Thau Sheu, Yuan-Soon Ho, Sri Rahayu, and Jungshan Chang. 2022. "Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers" Pharmaceutics 14, no. 4: 839. https://doi.org/10.3390/pharmaceutics14040839

Kan, T.-C., Lin, M.-H., Cheng, C.-C., Lu, J.-W., Sheu, M.-T., Ho, Y.-S., Rahayu, S., & Chang, J. (2022). Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers. Pharmaceutics, 14(4), 839. https://doi.org/10.3390/pharmaceutics14040839